A Phase Ib Study to Evaluate the Safety and Preliminary Efficacy of IL6-receptor Antibody Sarilumab in Combination With antiPD1 Antibody Cemiplimab for Patients With Non-small Cell Lung Cancer.
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Swiss Cancer Institute
Duke University
Montefiore Medical Center
Gustave Roussy, Cancer Campus, Grand Paris
Roswell Park Cancer Institute
The Netherlands Cancer Institute
Duke University
Henry Ford Health System
Mayo Clinic
Gruppo Oncologico Italiano di Ricerca Clinica
Emory University
Intergroupe Francophone de Cancerologie Thoracique
Intergroupe Francophone de Cancerologie Thoracique
UNICANCER
Grey Wolf Therapeutics
Università Vita-Salute San Raffaele
Fundación GECP
Weill Medical College of Cornell University
City of Hope Medical Center
Icahn School of Medicine at Mount Sinai
Centre hospitalier de l'Université de Montréal (CHUM)
Vanderbilt-Ingram Cancer Center
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Jules Bordet Institute